

# Massimo Radin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8110430/publications.pdf>

Version: 2024-02-01

83  
papers

1,341  
citations

377584

21  
h-index

488211

31  
g-index

83  
all docs

83  
docs citations

83  
times ranked

1696  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. <i>Nature Reviews Rheumatology</i> , 2022, 18, 9-21.	3.5	21
2	Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 575-580.	0.4	5
3	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). <i>Thrombosis and Haemostasis</i> , 2022, 122, 1612-1620.	1.8	0
4	Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5379.	1.2	2
5	Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience. <i>Journal of Clinical Medicine</i> , 2022, 11, 2977.	1.0	6
6	Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease. <i>Arthritis Care and Research</i> , 2021, 73, 1804-1808.	1.5	7
7	Endothelial dysfunction and cardiovascular risk in lupus nephritis: New roles for old players?. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13441.	1.7	6
8	Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients. <i>Rheumatology</i> , 2021, 60, 1106-1113.	0.9	18
9	Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study. <i>Frontiers in Medicine</i> , 2021, 8, 621590.	1.2	1
10	Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss. <i>Lupus</i> , 2021, 30, 884-892.	0.8	3
11	Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 395-406.	1.3	6
12	16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2021, 30, 1314-1326.	0.8	9
13	POS0172â€¦THROMBIN GENERATION ASSAY AND LUPUS ANTICOAGULANT IDENTIFY DIFFERENT POPULATIONS OF PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 298.1-299.	0.5	1
14	Antiphospholipid Antibodies and Infection: Non Nova Sed Nove. <i>Frontiers in Immunology</i> , 2021, 12, 687534.	2.2	14
15	Reducing the diagnostic delay in Antiphospholipid Syndrome over time: a real world observation. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 280.	1.2	8
16	Improving the clinical accuracy in patients with antiphospholipid antibodies using anti-phosphatidylserine/prothrombin and anti-beta2 glycoprotein I domain and particle-based multi-analyte technology. <i>Thrombosis Research</i> , 2021, 202, 100-103.	0.8	6
17	Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies. <i>Immunologic Research</i> , 2021, 69, 372-377.	1.3	4
18	Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS). <i>European Journal of Internal Medicine</i> , 2021, 92, 134-136.	1.0	7

#	ARTICLE	IF	CITATIONS
19	Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review. <i>American Journal of Nephrology</i> , 2021, 52, 559-571.	1.4	15
20	Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies. <i>Lancet Rheumatology</i> , The, 2021, 3, e832.	2.2	13
21	Vedolizumab for the Management of Refractory Behçet's Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease. <i>Frontiers in Immunology</i> , 2021, 12, 769785.	2.2	6
22	Quality of life measures in Systemic Lupus Erythematosus: A systematic review. <i>Reumatismo</i> , 2021, 73, .	0.4	2
23	Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study). <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 938-946.	0.4	1
24	Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	1
25	Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring. <i>Autoimmunity Reviews</i> , 2020, 19, 102449.	2.5	10
26	Treatment of antiphospholipid syndrome. <i>Clinical Immunology</i> , 2020, 221, 108597.	1.4	11
27	Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2020, 19, 102641.	2.5	13
28	The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2921-2928.	1.9	7
29	Genetic Factors in Antiphospholipid Syndrome: Preliminary Experience with Whole Exome Sequencing. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9551.	1.8	11
30	Validation of the Particle-Based Multi-Analyte Technology for Detection of Anti-PhosphatidylSerine/Prothrombin Antibodies. <i>Biomedicines</i> , 2020, 8, 622.	1.4	6
31	Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp's Usability Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3469.	1.2	5
32	Hydroxychloroquine reduces IL-6 and pro-thrombotic status. <i>Autoimmunity Reviews</i> , 2020, 19, 102555.	2.5	7
33	Antiphospholipid Syndrome Is Still a Rare Disease? Estimated Prevalence in the Piedmont and Aosta Valley Regions of Northwest Italy: Comment on the Article by Duarte-García et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 1774-1776.	2.9	12
34	Antiphosphatidylserine/Prothrombin Antibodies: An Update on Their Association with Clinical Manifestations of Antiphospholipid Syndrome. <i>Thrombosis and Haemostasis</i> , 2020, 120, 592-598.	1.8	41
35	Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients. <i>Autoimmunity Reviews</i> , 2020, 19, 102488.	2.5	5
36	Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global Antiphospholipid Syndrome Score. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 553-556.	1.6	13

#	ARTICLE	IF	CITATIONS
37	Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. <i>Journal of Nephrology</i> , 2020, 33, 757-762.	0.9	6
38	A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution. <i>Rheumatology</i> , 2020, 59, 2412-2418.	0.9	19
39	Filling the gap in antiphospholipid syndrome diagnosis: a patient's story. <i>Lupus</i> , 2020, 29, 236-238.	0.8	4
40	Global antiphospholipid syndrome score and anti-β <sub>2</sub> -glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study. <i>Lupus</i> , 2020, 29, 676-685.	0.8	13
41	Is air pollution affecting the disease activity in patients with systemic lupus erythematosus? State of the art and a systematic literature review. <i>European Journal of Rheumatology</i> , 2020, 7, 31-34.	1.3	14
42	The potential role of SLE-key test in identifying patients with Systemic Lupus Erythematosus: Results from a prospective, real-world experience. <i>European Journal of Internal Medicine</i> , 2019, 68, e12-e14.	1.0	1
43	Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 6308-6318.	1.6	15
44	IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients. <i>Frontiers in Medicine</i> , 2019, 6, 211.	1.2	5
45	Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1920-1926.	1.8	13
46	Pregnancy outcomes in mixed connective tissue disease: a multicentre study. <i>Rheumatology</i> , 2019, 58, 2000-2008.	0.9	10
47	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.	1.6	79
48	Translational validation of the Global Antiphospholipid Syndrome Score in patients with thrombotic APS. <i>Rheumatology</i> , 2019, 58, 1870-1872.	0.9	1
49	Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study. <i>Frontiers in Immunology</i> , 2019, 10, 376.	2.2	34
50	Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1004-1006.	0.5	23
51	Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 741-744.	1.6	12
52	Severe Multi-Organ Failure and Hypereosinophilia: When to Call It "Idiopathic". <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2018, 6, 232470961875834.	0.3	2
53	Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis. <i>Rheumatology</i> , 2018, 57, 661-665.	0.9	49
54	Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 117-120.	1.6	42

#	ARTICLE	IF	CITATIONS
55	Safety of outpatient percutaneous native renal biopsy in systemic autoimmune diseases: results from a monocentric cohort. <i>Lupus</i> , 2018, 27, 1393-1394.	0.8	7
56	Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. <i>Haematologica</i> , 2018, 103, 908-918.	1.7	30
57	The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study. <i>European Journal of Neurology</i> , 2018, 25, 320-325.	1.7	24
58	Prevalence and Thrombotic Risk Assessment of Anti-Î2 Glycoprotein I Domain I Antibodies: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 466-474.	1.5	60
59	Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223302.	0.2	1
60	Thrombotic antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 21-27.	0.8	3
61	Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1694-1695.	0.5	28
62	Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients. <i>Thrombosis Research</i> , 2018, 170, 28-31.	0.8	1
63	Recent advances in the management of systemic lupus erythematosus. <i>F1000Research</i> , 2018, 7, 970.	0.8	23
64	Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiology. <i>European Journal of Rheumatology</i> , 2018, 5, 92-95.	1.3	14
65	Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. <i>Internal and Emergency Medicine</i> , 2017, 12, 1-7.	1.0	28
66	Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review. <i>Autoimmunity Reviews</i> , 2017, 16, 287-293.	2.5	60
67	Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: A systematic review. <i>Autoimmunity Reviews</i> , 2017, 16, 469-477.	2.5	34
68	Infodemiology of systemic lupus erythematosus using Google Trends. <i>Lupus</i> , 2017, 26, 886-889.	0.8	32
69	Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. <i>Rheumatology International</i> , 2017, 37, 1249-1255.	1.5	61
70	Antiphospholipid antibodies: crossroads between autoimmunity and infections?. <i>Internal and Emergency Medicine</i> , 2017, 12, 557-558.	1.0	0
71	Antiphospholipid antibodies negativization: time for testing for non-criteria aPL?. <i>Lupus</i> , 2017, 26, 1457-1458.	0.8	6
72	The adjusted Global Antiphospholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2017, 240, 72-77.	0.8	48

#	ARTICLE	IF	CITATIONS
73	Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control Trials. <i>Clinical Drug Investigation</i> , 2017, 37, 519-524.	1.1	30
74	Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. <i>BioDrugs</i> , 2017, 31, 37-49.	2.2	30
75	What can Google and Wikipedia tell us about a disease? Big Data trends analysis in Systemic Lupus Erythematosus. <i>International Journal of Medical Informatics</i> , 2017, 107, 65-69.	1.6	25
76	Current insights in obstetric antiphospholipid syndrome. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 397-403.	0.9	41
77	Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconversion?. <i>Autoimmunity Reviews</i> , 2017, 16, 1109-1114.	2.5	19
78	Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. <i>Internal and Emergency Medicine</i> , 2017, 12, 1101-1108.	1.0	14
79	High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study. <i>American Journal of Nephrology</i> , 2017, 46, 108-113.	1.4	24
80	Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 55-69.	0.5	1
81	AB1014...Safety of outpatient percutaneous native renal biopsy in patients with systemic autoimmune diseases: results from a monocentric cohort. , 2017, , .		0
82	The 4 plus 2 rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study. <i>Oncotarget</i> , 2017, 8, 52072-52077.	0.8	15
83	Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. <i>Clinical and Molecular Allergy</i> , 2016, 14, 6.	0.8	37